Age-Related Macular Degeneration (ARMD) Treatments

Find Age-Related Macular Degeneration (ARMD) Treatments

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments

Treatment Overview

There is currently no cure for macular degeneration. Macular degeneration is a chronic, progressive disease. Patients with early age-related macular degeneration that are treated early may not progress to advanced vision loss. Treatment for macular degeneration is focused on slowing progression of the disease.

There are two types of macular degeneration:

Dry macular degeneration, is the most common type of macular degeneration. Dry macular degeneration gradually causes vision loss.

Wet macular degeneration is the less common and more serious type of macular degeneration. Wet macular degeneration causes scarring that rapidly leads to vision loss.

Types of Treatments

Treatment for dry or wet age-related macular degeneration includes:

Vitamin regimens, such as

  • Beta-carotene, or Vitamin A
  • Copper
  • Vitamin C
  • Vitamin E
  • Lutein
  • Zeaxanthin for smokers
  • Zinc oxide

Anti-vascular endothelial growth factor therapy, which are drugs given by injection into the eye that stop the growth of abnormal blood vessels. Anti-vascular endothelial grown factory therapy may help to restore lost vision.

Laser and photodynamic therapy, which use a light-activated drug, verteporfin, to seal the leaky blood vessels.

Intravitreal injections of drugs, such as bevacizumab, aflibercept, or ranibizumab, which may be given with or without laser therapy. Intravitreal means the drug is injected directly into the eye.

Assistive devices that may be needed for patients with macular degeneration include:

  • Enhanced lighting
  • Handheld magnifiers
  • High-contrast watches
  • Large print books and newspapers
  • Large type on computers and/or talking computers
  • Magnifying spectacles
  • Stand magnifiers

Surgery may be possible for selected patients with macular degeneration, in which an implantable miniature telescope may be implanted into the eye to help improve vision and quality of life.

Occupational therapy to assist with work accommodations, retraining, and job modifications for patients with macular degeneration.

Vision rehabilitation to assist with vision training, activities of daily living, and to provide modifications to the living environment for patients with macular degeneration.

Alternative and complementary therapies, such as vitamin D, vitamin B12, and omega-3 fatty acids, may help to reduce the progression of macular degeneration.

New, Experimental Treatments

Researchers are currently working on new gene therapies for the treatment of macular degeneration.

Long-Term Follow Up

Ongoing, long-term follow-up is an essential part of treatment for patients with macular degeneration to monitor disease progression and treatment effectiveness.

Sources

This content was written by the MediFind Medical Team. Last updated: 6/9/2022

Medications for Age-Related Macular Degeneration (ARMD)

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Age-Related Macular Degeneration (ARMD).

Found 8 Approved Drugs for Age-Related Macular Degeneration (ARMD)

Ranibizumab

Brand Names
Lucentis, Byooviz, Susvimo, Cimerli

Ranibizumab

Brand Names
Lucentis, Byooviz, Susvimo, Cimerli
Form: Injection
Method of administration: Intravitreal
FDA approval date: June 30, 2006
Classification: Vascular Endothelial Growth Factor Inhibitor
CIMERLI is indicated for the treatment of patients with: CIMERLI, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD).

Aflibercept

Brand Names
Eylea, Opuviz, Zaltrap, Pavblu

Aflibercept

Brand Names
Eylea, Opuviz, Zaltrap, Pavblu
Form: Injection, Solution
Method of administration: Intravitreal, Intravenous
FDA approval date: November 21, 2011
Classification: Vascular Endothelial Growth Factor Inhibitor
EYLEA HD is indicated for the treatment of: EYLEA HD is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD).

Beovu

Generic Name
Brolucizumab

Beovu

Generic Name
Brolucizumab
Form: Injection
Method of administration: Intravitreal
FDA approval date: July 26, 2018
BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD).

Vabysmo

Generic Name
Faricimab

Vabysmo

Generic Name
Faricimab
Form: Injection
Method of administration: Intravitreal
FDA approval date: January 28, 2022
VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with: VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD).

Visudyne

Generic Name
Verteporfin

Visudyne

Generic Name
Verteporfin
Form: Injection
Method of administration: Intravenous
FDA approval date: April 12, 2000
Classification: Photoenhancer
VISUDYNE ® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate VISUDYNE for the treatment of predominantly occult subfoveal CNV. VISUDYNE (verteporfin for injection) therapy is a photoenhancer indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. ( 1 )
Showing 1-5 of 8
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances
  1. Homepage
  2. Age-Related Macular Degeneration (ARMD) Treatments
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved